[晚期肺癌ALK激活模式改变及靶向治疗
研究进展]。

Q4 Medicine
Aojiao Wei, Bo Jiang, Yurong Huang, Mengyun Liu, Jing Yan, Yuanyuan Zhao, Wenjie He
{"title":"[晚期肺癌ALK激活模式改变及靶向治疗\u2029研究进展]。","authors":"Aojiao Wei, Bo Jiang, Yurong Huang, Mengyun Liu, Jing Yan, Yuanyuan Zhao, Wenjie He","doi":"10.3779/j.issn.1009-3419.2024.102.45","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer is the most common cancer in China and even in the world, and it is also the main cause of cancer death. Patients with anaplastic lymphoma kinase (ALK) gene alterations have the opportunity to receive molecularly targeted therapies. The inhibitors of anaplastic lymphoma kinase, such as ALK-tyrosine kinase inhibitors (ALK-TKIs) significantly prolong the survival of patients. ALK gene variant types include point mutation, amplification, fusion/rearrangement, and ALK fusion is more common than other types. However, the effect of different types of gene changes in molecular targeted therapy is different. Therefore, this paper introduced the relevant contents of different variants of ALK gene, focused on the research progress of targeted therapy, and proposed the future development direction.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 12","pages":"940-946"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839494/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Research Progress of ALK Activation Pattern Changes and Targeted Therapy \\u2029in Advanced Lung Cancer].\",\"authors\":\"Aojiao Wei, Bo Jiang, Yurong Huang, Mengyun Liu, Jing Yan, Yuanyuan Zhao, Wenjie He\",\"doi\":\"10.3779/j.issn.1009-3419.2024.102.45\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Lung cancer is the most common cancer in China and even in the world, and it is also the main cause of cancer death. Patients with anaplastic lymphoma kinase (ALK) gene alterations have the opportunity to receive molecularly targeted therapies. The inhibitors of anaplastic lymphoma kinase, such as ALK-tyrosine kinase inhibitors (ALK-TKIs) significantly prolong the survival of patients. ALK gene variant types include point mutation, amplification, fusion/rearrangement, and ALK fusion is more common than other types. However, the effect of different types of gene changes in molecular targeted therapy is different. Therefore, this paper introduced the relevant contents of different variants of ALK gene, focused on the research progress of targeted therapy, and proposed the future development direction.\\u2029.</p>\",\"PeriodicalId\":39317,\"journal\":{\"name\":\"中国肺癌杂志\",\"volume\":\"27 12\",\"pages\":\"940-946\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839494/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国肺癌杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3779/j.issn.1009-3419.2024.102.45\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2024.102.45","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

肺癌是中国乃至世界上最常见的癌症,也是癌症死亡的主要原因。间变性淋巴瘤激酶(ALK)基因改变的患者有机会接受分子靶向治疗。间变性淋巴瘤激酶抑制剂,如alk -酪氨酸激酶抑制剂(ALK-TKIs)可显著延长患者的生存期。ALK基因变异类型包括点突变、扩增、融合/重排,ALK融合比其他类型更常见。然而,不同类型的基因改变在分子靶向治疗中的作用是不同的。因此,本文介绍了ALK基因不同变异的相关内容,重点介绍了靶向治疗的研究进展,并提出了未来的发展方向。
。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Research Progress of ALK Activation Pattern Changes and Targeted Therapy 
in Advanced Lung Cancer].

Lung cancer is the most common cancer in China and even in the world, and it is also the main cause of cancer death. Patients with anaplastic lymphoma kinase (ALK) gene alterations have the opportunity to receive molecularly targeted therapies. The inhibitors of anaplastic lymphoma kinase, such as ALK-tyrosine kinase inhibitors (ALK-TKIs) significantly prolong the survival of patients. ALK gene variant types include point mutation, amplification, fusion/rearrangement, and ALK fusion is more common than other types. However, the effect of different types of gene changes in molecular targeted therapy is different. Therefore, this paper introduced the relevant contents of different variants of ALK gene, focused on the research progress of targeted therapy, and proposed the future development direction.
.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中国肺癌杂志
中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.40
自引率
0.00%
发文量
5131
审稿时长
14 weeks
期刊介绍: Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信